Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4923MR)

This product GTTS-WQ4923MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4923MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2881MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ1813MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ11641MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ9299MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ8862MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ1353MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ3747MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ208MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 13C5.5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW